Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dermira
Marketing
Eli Lilly, Incyte's Olumiant notches atopic dermatitis trial win
Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?
Kyle Blankenship
Jan 27, 2020 10:30am
Lilly inks $1.1B Dermira deal as biopharma M&A gets underway
Jan 10, 2020 11:42am
Condé Nast's new digital buying plan scores with pharma
Dec 16, 2019 7:53am
Can Dupixent steal half of a $21B eczema market? Not so fast
Dec 11, 2019 10:42am
Amgen, GSK advance to #FierceMadness Elite 8
Mar 27, 2019 10:55am
Dermira taps real patients in first ads for Qbrexza
Mar 25, 2019 10:11am